FDA ap­proves Ipsen's ul­tra-rare dis­ease drug palo­varotene

The FDA gave a nod of ap­proval to Ipsen’s treat­ment for the ul­tra-rare dis­ease fi­brodys­pla­sia os­si­f­i­cans pro­gres­si­va though reg­u­la­tors have ex­pressed con­cerns at least twice about the safe­ty and ef­fi­ca­cy of the drug.

“For the first time doc­tors have an ap­proved med­i­cine avail­able to them, shown to re­duce the for­ma­tion of new, ab­nor­mal bone growth, known as het­ero­topic os­si­fi­ca­tion (HO), which caus­es de­bil­i­tat­ing mo­bil­i­ty chal­lenges and has a dev­as­tat­ing im­pact on the lives of peo­ple with FOP,” Howard May­er, head of R&D at Ipsen, said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER